FrancophonIA/ELRC3.0 huggingface dataset:
English: Corticosteroids (systemic route) Reduction of the antihypertensive effect.
Latvian: Antihipertensīvās iedarbības samazināšanās.
English: Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Latvian: Pacientēm, kuras plāno grūtniecību, līdzšinējā terapija jāmaina pret alternatīvu antihipertensīvu terapiju ar vispāratzītu drošuma raksturojumu lietošanai grūtniecības laikā, ja vien turpmāka angiotenzīna II receptoru antagonistu lietošana netiek uzskatīta par būtisku.
English: INFORMATION IN BRAILLE Telmisartan Actavis 80 mg
Latvian: Telmisartan Actavis 80 mg
English: INFORMATION IN BRAILLE Telmisartan Actavis 20 mg
Latvian: Telmisartan Actavis 20 mg
English: How to take Telmisartan Actavis
Latvian: Ko Telmisartan Actavis satur
English: MARKETING AUTHORISATION NUMBER(S) EU/1/10/639/029 (30 tablets container) EU/1/10/639/030 (250 tablets container)
Latvian: 12. REĢISTRĀCIJAS NUMURS(I) EU/1/10/639/029 (30 tabletes konteinerā) EU/1/10/639/030 (250 tabletes konteinerā)
English: PHARMACEUTICAL FORM Tablet
Latvian: Etiķete tablešu konteineram
English: MARKETING AUTHORISATION NUMBER(S) EU/1/10/639/009 (30 tablets container) EU/1/10/639/010 (250 tablets container)
Latvian: 12. REĢISTRĀCIJAS NUMURS(I) EU/1/10/639/009 (30 tabletes konteinerā) EU/1/10/639/010 (250 tabletes konteinerā)
English: Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
Latvian: Alone and in combination with Ramipril Global Endpoint Trial) un VA NEPHRON-D (The Veterans
English: MARKETING AUTHORISATION NUMBER(S) EU/1/10/639/019 (30 tablets container) EU/1/10/639/020 (250 tablets container)
Latvian: 12. REĢISTRĀCIJAS NUMURS(I) EU/1/10/639/019 (30 tabletes konteinerā) EU/1/10/639/020 (250 tabletes konteinerā)
English: No posology adjustment is required for patients with mild to moderate renal impairment.
Latvian: Pacientiem ar viegliem līdz vidēji smagiem nieru darbības traucējumiem devas pielāgošana nav nepieciešama.
English: ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
Latvian: AKE inhibitoru vai angiotenzīna II receptoru blokatoru pacientiem ar 2. tipa cukura diabētu un hronisku nieru slimību, sirds - asinsvadu sistēmas slimību vai abām šīm slimībām kopā.
English: Al/Al blisters: Store in the original package in order to protect from light.
Latvian: Iepakojuma veids un saturs Al/Al blisteri:
English: For treatment of high blood pressure, the usual dose of Telmisartan Actavis for most patients is one 40 mg tablet once a day to control blood pressure over the 24 hour period.
Latvian: Telmisartan Actavis deva vairumam pacientu ir viena 40 mg tablete vienu reizi dienā.
English: Telmisartan Actavis 40 mg tablets Telmisartan
Latvian: Telmisartan Actavis 40 mg tabletes telmisartanum
English: Telmisartan Actavis should be used only with caution in patients with mild to moderate hepatic impairment.
Latvian: Pacientiem ar viegliem līdz vidēji smagiem aknu darbības traucējumiem Telmisartan Actavis jālieto piesardzīgi.
English: Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema); these side effects are rare (may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately.
Latvian: Šīs blakusparādības ir reti sastopamas (var rasties ne vairāk kā 1 pacientam no 1000), bet ir ārkārtīgi nopietnas un pieprasa nekavējoties pārtraukt zāļu lietošanu un meklēt ārsta palīdzību.
English: Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood.
Latvian: Urīnceļu infekcijas, augšējo elpceļu infekcijas (piemēram, rīkles iekaisums, deguna blakusdobumu iekaisums, saaukstēšanās), sarkano asins šūnu skaita samazināšanās (anēmija), palielināts kālija līmenis, iemigšanas grūtības, skumju sajūta (depresija), ģībšana (sinkope), vērpšanās sajūta (vertigo), lēna sirdsdarbība (bradikardija), pazemināts asinsspiediens (hipotensija), pacientiem, kuriem tiek ārstēts paaugstināts asinsspiediens, reibonis pieceļoties (ortostatiska hipotensija), elpas trūkums, klepus, sāpes vēderā, caureja, diskomforta sajūta vēderā, vēdera uzpūšanās, vemšana, nieze, pastiprināta svīšana, zāļu izraisīti izsitumi, muguras sāpes, muskuļu krampji, muskuļu sāpes (mialģija), nieru darbības traucējumi, tai skaitā akūta nieru mazspēja, sāpes krūškurvī, vājums un palielināts kreatinīna līmenis asinīs.
English: Telmisartan Actavis 20 mg tablets Telmisartan
Latvian: Telmisartan Actavis 20 mg tabletes telmisartanum
English: NAME OF THE MARKETING AUTHORISATION HOLDER Actavis logo
Latvian: REĢISTRĀCIJAS APLIECĪBAS ĪPAŠNIEKA NOSAUKUMS
English: Al/Al blister packs: 14, 28, 30, 56, 84, 90, 98 and 100 tablets.
Latvian: Al/Alblisteriepakojumi: 14, 28, 30, 56, 84, 90, 98 un100 tabletes Tablešu trauciņi: 30 un 250 tabletes.
English: Anaphylactic reaction , hypersensitivity Metabolism and nutrition disorders Uncommon: Rare:
Latvian: Elpošanas sistēmas traucējumi, krūšu kurvja un videnes slimības Retāk:
English: Telmisartan Actavis 80 mg tablets Telmisartan
Latvian: Telmisartan Actavis 80 mg tabletes
English: EU/1/10/639/001 (14 tablets blister) EU/1/10/639/002 (28 tablets blister) EU/1/10/639/003 (30 tablets blister) EU/1/10/639/004 (56 tablets blister) EU/1/10/639/005 (84 tablets blister) EU/1/10/639/006 (90 tablets blister) EU/1/10/639/007 (98 tablets blister) EU/1/10/639/008 (100 tablets blister)
Latvian: EU/1/10/639/001 (14 tabletes blisterī) EU/1/10/639/002 (28 tabletes blisterī) EU/1/10/639/003 (30 tabletes blisterī) EU/1/10/639/004 (56 tabletes blisterī) EU/1/10/639/005 (84 tabletes blisterī) EU/1/10/639/006 (90 tabletes blisterī) EU/1/10/639/007 (98 tabletes blisterī) EU/1/10/639/008 (100 tabletes blisterī)
English: EU/1/10/639/021 (14 tablets blister) EU/1/10/639/022 (28 tablets blister) EU/1/10/639/023 (30 tablets blister) EU/1/10/639/024 (56 tablets blister) EU/1/10/639/025 (84 tablets blister) EU/1/10/639/026 (90 tablets blister) EU/1/10/639/027 (98 tablets blister) EU/1/10/639/028 (100 tablets blister)
Latvian: EU/1/10/639/021 (14 tabletes blisterī) EU/1/10/639/022 (28 tabletes blisterī) EU/1/10/639/023 (30 tabletes blisterī) EU/1/10/639/024 (56 tabletes blisterī) EU/1/10/639/025 (84 tabletes blisterī) EU/1/10/639/026 (90 tabletes blisterī) EU/1/10/639/027 (98 tabletes blisterī) EU/1/10/639/028 (100 tabletes blisterī)
English: The main risk factors for hyperkalaemia to be considered are: - Diabetes mellitus, renal impairment, age (> 70 years)
Latvian: Galvenie hiperkaliēmijas riska faktori, kas jāņem vērā: - Cukura diabēts, nieru darbības traucējumi, vecums (> 70 gadi) - Vienu vai vairāku citu zāļu, kas ietekmē renīna-angiotenzīna-aldosterona sistēmu, un/vai kāliju saturošu uztura bagātinātāju vienlaicīga lietošana.
English: NAME OF THE MEDICINAL PRODUCT Telmisartan Actavis 40 mg tablets
Latvian: Telmisartan Actavis 40 mg tabletes
English: EU/1/10/639/011 (14 tablets blister) EU/1/10/639/012 (28 tablets blister) EU/1/10/639/013 (30 tablets blister) EU/1/10/639/014 (56 tablets blister) EU/1/10/639/015 (84 tablets blister) EU/1/10/639/016 (90 tablets blister) EU/1/10/639/017 (98 tablets blister) EU/1/10/639/018 (100 tablets blister)
Latvian: EU/1/10/639/011 (14 tabletes blisterī) EU/1/10/639/012 (28 tabletes blisterī) EU/1/10/639/013 (30 tabletes blisterī) EU/1/10/639/014 (56 tabletes blisterī) EU/1/10/639/015 (84 tabletes blisterī) EU/1/10/639/016 (90 tabletes blisterī) EU/1/10/639/017 (98 tabletes blisterī) EU/1/10/639/018 (100 tabletes blisterī)
English: White, round, flat tablets with logo T on one side.
Latvian: Tabletes Baltas, apaļas, plakanas tabletes ar logo T vienā pusē.
English: PARTICULARS TO APPEAR ON THE OUTER AND IMMEDIATE PACKAGING Carton for tablet container
Latvian: Telmisartan Actavis ārējais izskats un iepakojums
English: - Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain 'water tablets'), ACE inhibitors (angiotensinconverting enzyme inhibitors, to treat high blood pressure), angiotensin II receptor antagonists (to treat high blood pressure), NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin (a medicine for thinning the blood), immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.
Latvian: - Zāles, kas var palielināt kālija līmeni asinīs, piemēram, sāls aizstājēji, kas satur kāliju, kāliju saudzējošie diurētiskie līdzekļi (noteiktas „urīndzenošas tabletes”), AKE inhibitori (angiotenzīnu konvertējošā enzīma inhibitori), angiotenzīna II receptoru antagonisti
English: If you take more Telmisartan Actavis than you should It is important to keep to the dose as prescribed by your doctor.
Latvian: Ja esat lietojis Telmisartan Actavis vairāk nekā noteikts
English: Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash,
Latvian: Sepse* (parasti dēvēta „par asins saindēšanos”, ir smaga infekcija ar visa organisma iesaisti iekaisumā), straujš ādas un gļotādas pietūkums (angioedēma tūska).
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Latvian: http://www.ema.europa.eu/.
English: NAME OF THE MEDICINAL PRODUCT Telmisartan Actavis 20 mg tablets
Latvian: Telmisartan Actavis 20 mg tabletes
English: EU/1/10/639/021 (14 tablets blister) EU/1/10/639/022 (28 tablets blister) EU/1/10/639/023 (30 tablets blister) EU/1/10/639/024 (56 tablets blister) EU/1/10/639/025 (84 tablets blister) EU/1/10/639/026 (90 tablets blister) EU/1/10/639/027 (98 tablets blister) EU/1/10/639/028 (100 tablets blister) EU/1/10/639/029 (30 tablets container) EU/1/10/639/030 (250 tablets container)
Latvian: EU/1/10/639/024 (56 tabletes blisterī) EU/1/10/639/025 (84 tabletes blisterī) EU/1/10/639/026 (90 tabletes blisterī) EU/1/10/639/027 (98 tabletes blisterī) EU/1/10/639/028 (100 tabletes blisterī) EU/1/10/639/029 (30 tabletes konteinerā) EU/1/10/639/030 (250 tabletes konteinerā)
English: * The event may have happened by chance or could be related to a way that telmisartan works that is currently not known.
Latvian: Tas varēja notikt sagadīšanās pēc vai var būt saistīts ar vēl nezināmu mehānismu.
English: Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema); these side effects are rare (may affect up to 1 in1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately.
Latvian: Sepse* (parasti dēvēta „par asins saindēšanos”, ir smaga infekcija ar visa organisma iesaisti iekaisumā), straujš ādas un gļotādas pietūkums (angioedēma).
English: EU/1/10/639/011 (14 tablets blister) EU/1/10/639/012 (28 tablets blister) EU/1/10/639/013 (30 tablets blister) EU/1/10/639/014 (56 tablets blister) EU/1/10/639/015 (84 tablets blister) EU/1/10/639/016 (90 tablets blister) EU/1/10/639/017 (98 tablets blister) EU/1/10/639/018 (100 tablets blister) EU/1/10/639/019 (30 tablets container) EU/1/10/639/020 (250 tablets container)
Latvian: EU/1/10/639/014 (56 tabletes blisterī) EU/1/10/639/015 (84 tabletes blisterī) EU/1/10/639/016 (90 tabletes blisterī) EU/1/10/639/017 (98 tabletes blisterī) EU/1/10/639/018 (100 tabletes blisterī) EU/1/10/639/019 (30 tabletes konteinerā) EU/1/10/639/020 (250 tabletes konteinerā)
English: Gastrointestinal disorders Uncommon:
Latvian: Kuņģa-zarnu trakta traucējumi Retāk:
English: EU/1/10/639/001 (14 tablets blister) EU/1/10/639/002 (28 tablets blister) EU/1/10/639/003 (30 tablets blister) EU/1/10/639/004 (56 tablets blister) EU/1/10/639/005 (84 tablets blister) EU/1/10/639/006 (90 tablets blister) EU/1/10/639/007 (98 tablets blister) EU/1/10/639/008 (100 tablets blister) EU/1/10/639/009 (30 tablets container) EU/1/10/639/010 (250 tablets container)
Latvian: EU/1/10/639/005 (84 tabletes blisterī) EU/1/10/639/006 (90 tabletes blisterī) EU/1/10/639/007 (98 tabletes blisterī) EU/1/10/639/008 (100 tabletes blisterī) EU/1/10/639/009 (30 tabletes konteinerā) EU/1/10/639/010 (250 tabletes konteinerā)
English: 220 Hafnarfjörður
Latvian: Actavis Group PTC ehf. 220 Hafnarfjörður
English: Cardiovascular prevention
Latvian: Kardiovaskulāro notikumu riska mazināšana
English: Inventedname Strength Pharmaceutical Form
Latvian: Stiprums Zāļu forma
English: EU number
Latvian: (ES) numurs (Piešķirtais) nosaukums
English: The application for Mutual Recognition for Adartrel were submitted to Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden and United Kingdom.
Latvian: Adartrel savstarpējās atzīšanas pieteikums ir iesniegts Apvienotajā Karalistē, Austrijā, Beļģijā, Čehijā, Dānijā, Grieķijā, Igaunijā, Īrijā, Itālijā, Kiprā, Latvijā, Lietuvā, Luksemburgā, Maltā, Nīderlandē, Norvēģijā, Polijā, Portugālē, Slovākijā, Slovēnijā, Somijā, Spānijā, Ungārijā, Vācijā un Zviedrijā.
English: London, 3 April 2006 EMEA/CHMP/416317/2005
Latvian: Londona, 2006.gada 03.aprīlis EMEA/CHMP/416317/2005
English: A positive opinion was therefore adopted on 15 September 2005.
Latvian: Tādēļ 2005. gada 15. septembrī tika pieņemts labvēlīgs atzinums.
English: The final opinion was converted into a Decision by the European Commission on 3 April 2006.
Latvian: Galīgo atzinumu 2006.gada 3.aprīlī ietvēra Eiropas Komisijas lēmumā.
English: The Mutual Recognition Procedure started in September 2004.
Latvian: Savstarpējās atzīšanas procedūra ir uzsākta 2004. gada septembrī.
English: A Marketing Authorisation for Adartrel was granted to GlaxoSmithKline by France on 30 June 2004.
Latvian: Adartrel reģistrācijas apliecība ir izdota GlaxoSmithKline Francijā 2004. gada 30. jūnijā.
English: During its 12-15 September 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee was of the opinion that a marketing authorisation should be granted subject to certain conditions considered essential for the safe and effective use of the medicinal product.
Latvian: CHMP 2005. gada 12.-15. septembra sanāksmes laikā, ņemot vērā visus iesniegtos datus un zinātnisko apspriešanu komitejā, tā uzskatīja, ka reģistrācijas apliecība ir jāizsniedz, ievērojot dažus nosacījumus, kas uzskatāmi par būtiskiem šo zāļu drošai un efektīvai lietošanai.
English: The referral procedure was triggered by Spain and The Netherlands, who were of the opinion that this medicinal product might present a risk to public health since the safety and efficacy in long-term treatment of ropinirole in restless legs syndrome had not been demonstrated.
Latvian: Spānija un Nīderlande ierosināja pārskatīšanas procedūru, uzskatot, ka šīs zāles var apdraudēt sabiedrības veselību, jo nav pierādīts ropinirola nekaitīgums un efektivitāte, ilgstoši ārstējot nemierīgo kāju sindromu.
English: The arbitration procedure started on 15 December 2004.
Latvian: Arbitrāžas procedūra tika uzsākta 2004. gada 15. decembrī.
English: Adartrel is a selective dopamine agonist at the D2- and D3-dopamine receptor subtypes and is active both centrally and peripherally.
Latvian: Adatrel ir selektīvs dopamīna agonists, kas iedarbojas uz D2 - un D3-dopamīna receptoriem, tam piemīt gan centrālā, gan perifērā aktivitāte.
English: Supplementary information was provided by the Marketing Authorisation Holder on 18 March 2005.
Latvian: Reģistrācijas apliecības īpašnieks 2005. gada 18. martā sniedza papildu informāciju.
English: Conditions of the Marketing Authorisation are set out in Annex IV.
Latvian: Reģistrācijas apliecības nosacījumi ir izklāstīti IV pielikumā.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(2) REFERRAL Adartrel International Non-Proprietary Name (INN): Ropinirole
Latvian: PUNKTA ATTIECINĀŠANAS Adartrel Starptautiskais neaizsargātais nosaukums (SNN): ropinirols
English: The list of product names concerned is given in the Annex I. The scientific conclusions are provided in the Annex II, together with the Summary of Product Characteristics in the Annex III.
Latvian: Zinātniskie secinājumi ir izklāstīti II pielikumā, bet zāļu apraksts ir atrodams III pielikumā.
English: They included young and adult cats of various breeds, but not young kittens.
Latvian: Pētījumos iekļāva dažādu sugu jaunus un pieaugušus kaķus, bet ne mazus kaķēnus.
English: The vaccine helps to reduce the symptoms of the diseases and also helps to reduce viral excretion in case of calicivirus infection for one year after vaccination.
Latvian: Vakcīna palīdz mazināt slimību simptomus, kā arī vīrusa izdalīšanos kalicivīrusa infekcijas gadījumā vienu gadu pēc vakcinācijas.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Purevax RC on 23 February 2005.
Latvian: Eiropas Komisija 2005. gada 23. februārī apstiprināja Purevax RC reģistrāciju, kas derīga visā Eiropas Savienībā.
English: • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains).
Latvian: • inaktivētus (nedzīvus) kalicivirozes antigēnus (FCV 431 un G1 celmu).
English: When a cat is given the vaccine, the immune system recognises the weakened or killed viruses as ‘foreign' and makes antibodies against them.
Latvian: Kad kaķim ievada vakcīnu, imūnsistēma atpazīst novājinātos vai nedzīvos vīrusus kā “svešus” un izstrādā pret tiem antivielas.
English: When exposed to any of these viruses later in life, the cat will either not become infected or have a much less serious infection.
Latvian: Vēlāk saskaroties ar kādu no šiem vīrusiem, kaķis vai nu neinficējas, vai arī infekcija ir mazāk smaga.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax RC exceed the risks for the approved indications and recommended that Purevax RC be given a marketing authorisation.
Latvian: Veterināro zāļu komiteja (CVMP) secināja, ka ieguvums, lietojot Purevax RC, pārsniedz šo zāļu radīto risku apstiprinātajās indikācijās, un ieteica izsniegt Purevax RC reģistrācijas apliecību.
English: In laboratory conditions Purevax RC was demonstrated to provide protection against the diseases listed above.
Latvian: Laboratorijas apstākļos pierādīja, ka Purevax RC nodrošina aizsardzību pret iepriekš minētajām slimībām.
English: Purevax RC should not be used in pregnant cats.
Latvian: Purevax RC nedrīkst lietot grūsnām kaķenēm.
English: Purevax RC is a vaccine.
Latvian: Purevax RC ir vakcīna.
English: The effectiveness of Purevax RC has been studied in several trials in laboratory conditions where cats were vaccinated and infected with herpesvirus and calicivirus.
Latvian: Purevax RC efektivitāti vērtēja vairākos pētījumos laboratorijas apstākļos, kur kaķus vakcinēja un inficēja ar herpesvīrusu un kalicivīrusu.
English: In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses.
Latvian: Turpmāk, saskaroties ar šiem vīrusiem, imūnsistēma spēj ātrāk izstrādāt antivielas.
English: In the field, the studies of Purevax RC looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination.
Latvian: Purevax RC lauka pētījumos vērtēja vakcinācijas pamatshēmu (2 vakcīnas ar 3-4 nedēļu starplaiku) un revakcināciju.
English: Purevax RC is available as a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Latvian: Purevax RC ir pieejama kā liofilizāts (sasaldējot žāvētas granulas) un šķīdinātājs suspensijas injekcijām pagatavošanai.
English: Purevax RC is used to vaccinate cats from the age of 8 weeks against:
Latvian: Purevax RC lieto, lai kaķus, kas sasnieguši 8 nedēļu vecumu, vakcinētu pret šādām slimībām:
English: • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus).
Latvian: • kaķu kalicivirozi (gripai līdzīgu slimību ar mutes dobuma iekaisumu, ko izraisa kalicivīruss).
English: In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus and calicivirus infection remained stable at a high level or increased slightly.
Latvian: Pētījumā, kurā vērtēja revakcināciju, antivielu līmenis pret rinotraheīta vīrusu un kalicivīrusa infekciju saglabājās nemainīgi augsts vai nedaudz palielinājās.
English: Why has Purevax RC been approved?
Latvian: Kāpēc Purevax RC tika apstiprinātas?
English: Purevax RC contains small amounts of weakened or killed viruses that cause feline rhinotracheitis and calicivirosis.
Latvian: Purevax RC nelielā daudzumā satur novājinātus vai nedzīvus vīrusus, kas izraisa kaķu rinotraheītu un kalicivirozi.
English: Purevax RC is a veterinary vaccine that contains:
Latvian: Purevax RC ir veterinārā vakcīna, kas satur šādas aktīvās vielas:
English: What benefit has Purevax RC shown during the studies?
Latvian: Kādi Purevax RC ieguvumi bija uzrādīti pētījumos?
English: In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus and calicivirus infection.
Latvian: Pamata vakcinācijas lauka pētījumā konstatēja antivielu daudzuma palielināšanos pret kaķu rinotraheīta herpesvīrusu un kalicivīrusa infekciju.
English: Other information about Purevax RC:
Latvian: Cita informācija par Purevax RC
English: Feline viral rhinotracheitis (live attenuated) and feline calicivirosis (inactivated) vaccine
Latvian: Kaķu infekciozā rinotraheīta (dzīva, novājināta) un kaķu kalicivirozes (inaktivētas) vakcīna
English: What is the risk associated with Purevax RC?
Latvian: Kāds risks pastāv, lietojot Purevax RC?
English: What is Purevax RC?
Latvian: Kas ir Purevax RC?
English: How does Purevax RC work?
Latvian: Kā Purevax RC darbojas?
English: For a full list of the side-effects reported with Purevax RC, see the package leaflet.
Latvian: Pilns visu Purevax RC izraisīto blakusparādību saraksts ir atrodams zāļu lietošanas instrukcijā.
English: How has Purevax RC been studied?
Latvian: Kā noritēja Purevax RC izpēte?
English: EMEA Number
Latvian: EMEA procedūras numurs Piešķirtais nosaukums
English: Invented name Strength Pharmaceutical Form Route of Administration
Latvian: Stiprums Zāļu forma
English: Influenza virus surface antigens (haemagglutinin and neuraminidase)*, inactivated, of the following strains: A/California/7/2009 (H1N1)pdm09- like strain (A/Brisbane/10/2010, wild type)
Latvian: Gripas vīrusa virsmas antigēni (hemaglutinīns un neiraminidāze)*, inaktivēti, satur šādus celmus: A/California/7/2009 (H1N1)pdm09 tipa celms (A/Brisbane/10/2010, dabiska tipa)